Chitosan nano-structure loaded with recombinant E. coli O157:H7 antigens as a vaccine candidate can effectively increase immunization capacity

References

• Bach SJ, McAllister TA, Veira DM. Transmission and control of Escherichia coli O157:H7—a review. Can J Anim Sci. 2002;82:475–490.
   Web of Science ®Google Scholar
• Pop M, Walker AW, Paulson J, et al. Diarrhea in young children from low-income countries leads to large-scale alterations in intestinal microbiota composition. Genome Biol. 2014;15:R76.
   PubMed Web of Science ®Google Scholar
• Garcia-Angulo VA, Kalita A, Torres AG. Advances in the development of enterohaemorrhagic Escherichia coli vaccines using murine models of infection. Vaccine. 2013;31:3229–3235.
   PubMed Web of Science ®Google Scholar
• Ellis RW, Brodeur BR. New bacterial vaccines. New York, NY: Springer Science & Business Media; 2012.
   Google Scholar
• Rojas-Lopez M, Monterio R, Pizza M, et al. Intestinal pathogenic Escherichia coli: insights for vaccine development. Front Microbiol. 2018;9:440.
   PubMed Web of Science ®Google Scholar
• Karmali MA. Infection by verocytotoxin-producing Escherichia coli. Clin Microbiol Rev. 1989;2:15–38.
   PubMed Web of Science ®Google Scholar
• Gyles C. Shiga toxin-producing Escherichia coli: An overview 1. J Animal Sci. 2007;85:E45–E62.
   PubMed Web of Science ®Google Scholar
• Boerlin P, McEwen SA, Boerlin-Petzold F, et al. Associations between virulence factors of Shiga toxin-producing Escherichia coli and disease in humans. J Clin Microbiol. 1999;37:497–503.
   PubMed Web of Science ®Google Scholar
• Obrig TG. Escherichia coli Shiga toxin mechanisms of action in renal disease. Toxins. 2010;2:2769–2794.
   PubMed Web of Science ®Google Scholar
• Johannes L, Römer W. Shiga toxins—from cell biology to biomedical applications. Nat Rev Microbiol. 2010;8:105.
   PubMed Web of Science ®Google Scholar
• Paton JC, Paton AW. Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections. Clin Microbiol Rev. 1998;11:450–479.
   PubMed Web of Science ®Google Scholar
• Mohawk KL, Melton-Celsa AR, Robinson CM, et al. Neutralizing antibodies to Shiga toxin type 2 (Stx2) reduce colonization of mice by Stx2-expressing Escherichia coli O157:H7. Vaccine. 2010;28:4777–4785.
   PubMed Web of Science ®Google Scholar
• Lu X, Skurnik D, Pozzi C, et al. A Poly-N-Acetylglucosamine − Shiga toxin broad-spectrum conjugate vaccine for Shiga toxin-producing Escherichia coli. MBio. 2014;5:e00974.
   PubMed Web of Science ®Google Scholar
• Kazemi R, Akhavian A, Amani J, et al. Immunogenic properties of trivalent recombinant protein composed of B-subunits of LT, STX-2, and CT toxins. Microb Infect. 2016;18:421–429.
   PubMed Web of Science ®Google Scholar
• Mejias MP, Ghersi G, Craig PO, et al. Immunization with a chimera consisting of the B subunit of Shiga toxin type 2 and brucella lumazine synthase confers total protection against Shiga toxins in mice. J Immunol. 2013;191:2403–2411.
   PubMed Web of Science ®Google Scholar
• Gao X, Cai K, Shi J, et al. Immunogenicity of a novel Stx2B–Stx1B fusion protein in a mice model of Enterohaemorrhagic Escherichia coli O157:H7 infection. Vaccine. 2009;27:2070–2076.
   PubMed Web of Science ®Google Scholar
• Dziva F, Vlisidou I, Crepin VF, et al. Vaccination of calves with EspA, a key colonisation factor of Escherichia coli O157:H7, induces antigen-specific humoral responses but does not confer protection against intestinal colonisation. Veter Microbiol. 2007;123:254–261.
   PubMed Web of Science ®Google Scholar
• Fan H-y, Wang L, Luo J, et al. Protection against Escherichia coli O157:H7 challenge by immunization of mice with purified Tir proteins. Mol Biol Rep. 2012;39:989–997.
   PubMed Web of Science ®Google Scholar
• Dean-Nystrom EA, Bosworth BT, Moon HW, et al. Escherichia coli O157:H7 requires intimin for enteropathogenicity in calves. Infect Immun. 1998;66:4560–4563.
   PubMed Web of Science ®Google Scholar
• Wan C-s, Zhou Y, Yu Y, et al. B‐cell epitope KT‐12 of enterohaemorrhagic Escherichia coli O157:H7: A novel peptide vaccine candidate. Microbiol Immunol. 2011;55:247–253.
   PubMed Web of Science ®Google Scholar
• Amani J, Salmanian AH, Rafati S, et al. Immunogenic properties of chimeric protein from espA, eae and tir genes of Escherichia coli O157:H7. Vaccine. 2010;28:6923–6929.
   PubMed Web of Science ®Google Scholar
• Eko FO, Witte A, Huter V, et al. New strategies for combination vaccines based on the extended recombinant bacterial ghost system. Vaccine. 1999;17:1643–1649.
   PubMed Web of Science ®Google Scholar
• Hajizade A, Ebrahami F, Salmanian A-H, et al. Nanoparticles in vaccine development. J Appl Biotechnol Rep. 2015;1:125–134.
   Google Scholar
• Sekhon BS, Saluja V. Nanovaccines-an overview. Int J Pharm Front Res. 2011;1:101–109.
   Google Scholar
• Metcalfe SM, Fahmy TM. Targeted nanotherapy for induction of therapeutic immune responses. Trends Mol Med. 2012;18:72–80.
   PubMed Web of Science ®Google Scholar
• Vinsova J, Vavrikova E. Chitosan derivatives with antimicrobial, antitumour and antioxidant activities-a review. Cpd. 2011;17:3596–3607.
   Web of Science ®Google Scholar
• Xu Y, Du Y. Effect of molecular structure of chitosan on protein delivery properties of chitosan nanoparticles. Int J Pharmac. 2003;250:215–226.
   PubMed Web of Science ®Google Scholar
• van der Lubben IM, Verhoef JC, Borchard G, et al. Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur J Pharma Sci. 2001;14:201–207.
   PubMed Web of Science ®Google Scholar
• Qi L, Xu Z, Jiang X, et al. Preparation and antibacterial activity of chitosan nanoparticles. Carbohydr Res. 2004;339:2693–2700.
   PubMed Web of Science ®Google Scholar
• Zhao L, Seth A, Wibowo N, et al. Nanoparticle vaccines. Vaccine. 2014;32:327–337.
   PubMed Web of Science ®Google Scholar
• Sahdev P, Ochyl LJ, Moon JJ. Biomaterials for nanoparticle vaccine delivery systems. Pharma Res. 2014;31:2563–2582.
   Web of Science ®Google Scholar
• Doavi T, Mousavi SL, Kamali M, et al. Chitosan-based intranasal vaccine against Escherichia coli O157:H7. Iranian Biomed J. 2016;20:97.
   PubMedGoogle Scholar
• Zhang X-h, He K-w, Zhang S-x, et al. Subcutaneous and intranasal immunization with Stx2B–Tir–Stx1B–Zot reduces colonization and shedding of Escherichia coli O157:H7 in mice. Vaccine. 2011;29:3923–3929.
   PubMed Web of Science ®Google Scholar
• Kruger NJ. The Bradford method for protein quantitation. In: The protein protocols handbook. Totowa (NJ): Springer; 2002. p. 15–21.
   Google Scholar
• Tu W, Li T, Wang Q, et al. A simple method for expression and purification of Shiga toxin 1 (Stx1) with biological activities by using a single‐promoter vector and native signal peptide. Biotechnol Appl Biochem. 2016;63:539–545.
   PubMed Web of Science ®Google Scholar
• McFarland J. The nephelometer: an instrument for estimating the number of bacteria in suspensions used for calculating the opsonic index and for vaccines. J Am Med Assoc. 1907;49:1176–1178.
   Google Scholar
• Mehr KS, Mousavi SL, Rasooli I, et al. A DNA vaccine against Escherichia coli O157:H7. Iranian Biomed J. 2012;16:133.
   PubMedGoogle Scholar
• McNeilly TN, Mitchell MC, Rosser T, et al. Immunization of cattle with a combination of purified intimin-531, EspA and Tir significantly reduces shedding of Escherichia coli O157:H7 following oral challenge. Vaccine. 2010;28:1422–1428.
   PubMed Web of Science ®Google Scholar
• Amani J, Mousavi SL, Rafati S, et al. Immunogenicity of a plant-derived edible chimeric EspA, Intimin and Tir of Escherichia coli O157:H7 in mice. Plant Sci. 2011;180:620–627.
   PubMed Web of Science ®Google Scholar
• Xing L, Fan Y-T, Zhou T-J, et al. Chemical modification of chitosan for efficient vaccine delivery. Molecules. 2018;23:229.
   PubMed Web of Science ®Google Scholar
• Liu M. DNA vaccines: a review. J Intern Med. 2003;253:402–410.
   PubMed Web of Science ®Google Scholar
• Nandedkar TD. Nanovaccines: recent developments in vaccination. J Biosci. 2009;34:995–1003.
   PubMed Web of Science ®Google Scholar
• Yoo M-K, Kang S-K, Choi J-H, et al. Targeted delivery of chitosan nanoparticles to Peyer’s patch using M cell-homing peptide selected by phage display technique. Biomaterials. 2010;31:7738–7747.
   PubMed Web of Science ®Google Scholar
• Bhattarai N, Gunn J, Zhang M. Chitosan-based hydrogels for controlled, localized drug delivery. Adv Drug Deliv Rev. 2010;62:83–99.
   PubMed Web of Science ®Google Scholar
• Khanifar J, Hosseini RH, Kazemi R, et al. Prevention of EHEC infection by chitosan nano-structure coupled with synthetic recombinant antigen. J Microbiol Methods. 2019;157:100–107.
   PubMed Web of Science ®Google Scholar
• Potter AA, Klashinsky S, Li Y, et al. Decreased shedding of Escherichia coli O157:H7 by cattle following vaccination with type III secreted proteins. Vaccine. 2004;22:362–369.
   PubMed Web of Science ®Google Scholar
• Mejias MP, Cabrera G, Fernández-Brando RJ, et al. Protection of mice against Shiga toxin 2 (Stx2)-associated damage by maternal immunization with a Brucella lumazine synthase-Stx2 B subunit chimera. Infect Immun. 2014;82:1491–1499.
   PubMed Web of Science ®Google Scholar
• Ishikawa S, Kawahara K, Kagami Y, et al. Protection against Shiga toxin 1 challenge by immunization of mice with purified mutant Shiga toxin 1. Infect Immun. 2003;71:3235–3239.
   PubMed Web of Science ®Google Scholar
• Watarai S, Isogai E, Oguma K. Induction of intestinal IgA and IgG antibodies preventing adhesion of verotoxin‐producing Escherichia coli to Caco‐2 cells by oral immunization with liposomes. Lett Appl Microbiol. 2003;36:135–139.
   PubMed Web of Science ®Google Scholar